The potential for Pfizer to take over U.K. pharma giant AstraZeneca has already sent its prey's share price soaring and caused political ructions on both sides of the Atlantic – without an agreed deal on the table.
With the expiration of a three-month period during which Pfizer must stay away from AstraZeneca, under U.K. takeover law, on Tuesday, speculation that the maker of Viagra may eventually seal this deal has risen.
For Pfizer, the possibility for saving on its tax bill by headquartering in the U.K. for tax purposes, a process known as tax inversion, would be one of the biggest drivers behind such a deal, along with building up its cancer medicines portfolio.
There are a few ways this story may end. Pfizer and AstraZeneca spokespeople declined to comment.